How Pf-07304814 Turned a Solubility-limited Inhibitor Into an Iv Candidate
PF-00835231 potently inhibits the SARS-CoV-2 main protease, but low aqueous solubility, limited oral bioavailability, and a short projected half-life restricted its dosing options. Continuous intravenous infusion could provide minimum target exposure, yet higher doses required impractical volumes. Researchers therefore converted it into a phosphate prodrug. From active inhibitor to soluble prodrug Researchers created PF-07304814, later named…